Track Virios Therapeutics, LLC — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Virios Therapeutics, LLC VIRI · Stock Open Virios Therapeutics, LLC in new tab

0.1550 USD
Add to portfolio
EPS
-5.75
P/B
0.05
ROE
-119.56
Beta
1.58
Target Price
3.00 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-5.75
Book Value2.82
Price to Book0.05
Estimates
Forward P/E-0.97
Forward EPS-0.16
Target Mean Price3.00

DCF Valuation

Tweak assumptions to recompute fair value for Virios Therapeutics, LLC (VIRI)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Virios Therapeutics, LLC Logo Virios Therapeutics, LLC Analysis (VIRI)

United States Health Care Official Website Stock

Is Virios Therapeutics, LLC a good investment? Virios Therapeutics, LLC (VIRI) is currently trading at 0.1550 USD. Market analysts have a consensus price target of 3.00 USD. This suggests a potential upside from current levels.

Investor FAQ

Does Virios Therapeutics, LLC pay a dividend?

No, it does not currently pay a dividend.

What asset class is Virios Therapeutics, LLC?

Virios Therapeutics, LLC is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Exchange Ticker
NMS (United States) VIRI
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 9, 2024 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion